Literature DB >> 24688626

Refractory Postinflammatory Hyperpigmentation Treated Fractional CO2 Laser.

Yasemin Oram1, A Deniz Akkaya1.   

Abstract

OBJECTIVE: Postinflammatory hyperpigmentation is a reactive hypermelanosis of the skin that occurs as a consequence of an inflammatory process, such as acne, eczema, drug reactions, burns, chemical peelings, and laser applications. Although topical agents remain to be the first-line treatment of postinflammatory hyperpigmentation, treatment of recalcitrant cases is challenging. The Q-switched ruby laser, the low-dose Q-switched neodymium-doped yttrium aluminum garnet laser, and the fractional 1550nm erbium-doped fiber laser have been reported to improve postinflammatory hyperpigmentation. DESIGN/SETTING/PARTICIPANTS: The authors present a case of refractory postinflammatory hyperpigmentation successfully treated with two sessions of fractional CO2 laser in a 24-year-old woman with Fitzpatrick skin type III.
RESULTS: After two treatment sessions with a one-month interval, the lesion totally cleared without any complications.
CONCLUSION: Although many laser systems, including fractional CO2 lasers, can cause postinflammatory hyperpigmentation, they also can be very efficacious tools by using conservative laser settings and by providing appropriate post-treatment care in recalcitrant postinflammatory hyperpigmentation treatment.

Entities:  

Year:  2014        PMID: 24688626      PMCID: PMC3970832     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  8 in total

1.  Laser-induced transepidermal elimination of dermal content by fractional photothermolysis.

Authors:  Basil M Hantash; Vikramaditya P Bedi; Vasanthi Sudireddy; Steven K Struck; G Scott Herron; Kin Foong Chan
Journal:  J Biomed Opt       Date:  2006 Jul-Aug       Impact factor: 3.170

2.  Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study.

Authors:  Marije W Kroon; Bas S Wind; Arne A Meesters; Albert Wolkerstorfer; J P Wietze van der Veen; Jan D Bos; Allard C Van der Wal; Johan F Beek
Journal:  J Dermatolog Treat       Date:  2011-07-14       Impact factor: 3.359

3.  Treatment of post-inflammatory hyperpigmentation using 1064-nm Q-switched Nd:YAG laser with low fluence: report of three cases.

Authors:  S B Cho; S J Park; J S Kim; M J Kim; T S Bu
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-04-23       Impact factor: 6.166

4.  Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation after carbon dioxide laser resurfacing.

Authors:  Cameron K Rokhsar; David H Ciocon
Journal:  Dermatol Surg       Date:  2009-02-22       Impact factor: 3.398

Review 5.  Fractionated laser skin resurfacing treatment complications: a review.

Authors:  Andrei I Metelitsa; Tina S Alster
Journal:  Dermatol Surg       Date:  2010-01-19       Impact factor: 3.398

6.  Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation.

Authors:  Tracy M Katz; Leonard H Goldberg; Bahar F Firoz; Paul M Friedman
Journal:  Dermatol Surg       Date:  2009-08-13       Impact factor: 3.398

Review 7.  Postinflammatory hyperpigmentation: etiologic and therapeutic considerations.

Authors:  Valerie D Callender; Sharleen St Surin-Lord; Erica C Davis; Marissa Maclin
Journal:  Am J Clin Dermatol       Date:  2011-04-01       Impact factor: 7.403

8.  The degrees of UVB-induced erythema and pigmentation correlate linearly and are reduced in a parallel manner by topical anti-inflammatory agents.

Authors:  H Takiwaki; S Shirai; H Kohno; H Soh; S Arase
Journal:  J Invest Dermatol       Date:  1994-11       Impact factor: 8.551

  8 in total
  1 in total

1.  Evaluation of Efficacy and Safety of Low-Fluence Q-Switched 1064-nm Laser in Infra-orbital Hyperpigmentation Based on Biometric Parameters.

Authors:  Shiva Alavi; Azadeh Goodarzi; Mohammad Ali Nilforoushzadeh; Parvin Mansouri; Mohammad Amin Jafari; Somayeh Hejazi; Zahra Azizian
Journal:  J Lasers Med Sci       Date:  2022-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.